BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for MoonLake Immunotherapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-08 6:48 pm Sale |
2024-10-04 | 13D | MoonLake Immunotherapeutics MLTX |
BIOTECHNOLOGY VALUE FUND L P | 19,751,284 31.400% |
-2,000,000 (-9.19%) |
Filing |
| 2024-03-05 4:59 pm Unchanged |
2024-02-29 | 13D | MoonLake Immunotherapeutics MLTX |
BIOTECHNOLOGY VALUE FUND L P | 21,751,284 34.600% |
0 (Unchanged) |
Filing |
| 2023-06-30 4:41 pm Unchanged |
2023-06-27 | 13D | MoonLake Immunotherapeutics MLTX |
BIOTECHNOLOGY VALUE FUND L P | 21,751,284 35.800% |
0 (Unchanged) |
Filing |
| 2022-04-18 4:49 pm Purchase |
2022-04-05 | 13D | MoonLake Immunotherapeutics MLTX |
BIOTECHNOLOGY VALUE FUND L P | 21,751,284 58.900% |
21,751,284 (New Position) |
Filing |